Acrivon Therapeutics, Inc. Common Stock
NASDAQ:ACRVBiotechnology
Healthcare
$1.56 +3.16%
+$0.05 today
- Market cap
- $66.94M
- Beta
- 1.91
- P/E (TTM)
- -0.8
- EPS (TTM)
- -$2.00
52W Low $1.15High $3.56
Volume 0.61M
Average 0.60M
ACRV EBITDA Margin
EBITDA as a percentage of revenue.
No reported EBITDA Margin figures are available to summarize.
EBITDA Margin history
Percent of revenue · from the income statement
No EBITDA Margin data reported for this period type.
EBITDA Margin vs competitors
How ACRV compares with its peers on the latest reported figures
ACRV Competitors Peer median
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 18.5% | +115.0 pp | +94012.8 pp | |
| LTM Mar 2026 | -1298.7% | +1519.2 pp | -759.6 pp | |
CBUSCibus, Inc. | LTM Mar 2026 | -1453.8% | +4107.2 pp | +7193.6 pp |
| LTM Mar 2026 | -36154.2% | — | -37771.8 pp | |
ACRVAcrivon Therapeutics, Inc. Common Stock | FY2025 | — | — | — |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding ACRV) | -1376.3% | +1519.2 pp | +3217.0 pp | |
Competitors are the stored peer set for ACRV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 536K | 1.01M | 1.36M |
| Gross Profit | 0 | 0 | (536K) | (1.01M) | (1.36M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 13.72M | 23.95M | 45.49M | 63.99M | 59.99M |
| Selling, General & Admin | 2.47M | 8.71M | 21.21M | 25.21M | 24.12M |
| Operating Expenses | 16.18M | 32.66M | 66.7M | 88.19M | 82.76M |
| Depreciation & Amortization | 37K | 364K | 536K | 1.01M | 1.36M |
| EBITDA | (16.21M) | (30.8M) | (59.85M) | (79.55M) | (76.55M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (16.18M) | (32.66M) | (67.24M) | (89.2M) | (84.11M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 7.04M | 9.2M | 6.48M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (59K) | 1.49M | 6.85M | 8.64M | 6.21M |
| Income Before Tax | (16.24M) | (31.17M) | (60.39M) | (80.56M) | (77.91M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (16.24M) | (31.17M) | (60.39M) | (80.56M) | (77.91M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.26) | (1.42) | (2.74) | (2.10) | (2.02) |
| EPS (Diluted) | (1.26) | (1.42) | (2.74) | (2.10) | (2.02) |
| Weighted Avg Shares | 12.91M | 21.92M | 22.08M | 38.3M | 38.51M |
| Weighted Avg Shares (Diluted) | 12.91M | 21.92M | 22.08M | 38.3M | 38.51M |
Acrivon Therapeutics, Inc. Common Stock
NASDAQ:ACRV
Intrinsic Alpha fair value
Locked
Current Price
$1.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.